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costs and outcomes discounted at 5%, equals 33,622 PLN 
(7815 €) for each year of life gained. CONCLUSIONS: In a pop-
ulation of high risk NSTEMI patients, adding eptiﬁbatide is a
cost-effective way of achieving health beneﬁts in terms of car-
diovascular events avoided, and ultimately life years saved. This
result is much below thresholds accepted in Poland (60,000
PLN—dialysis).
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OBJECTIVES: To perform an economic evaluation of the use of
low dose acetylsalicylic acid (Adiro) in comparison with clopi-
dogrel (Plavix) in the prevention of cardiovascular events in
patients with a previous myocardial infarction (MI) using a cost-
effectiveness analysis in the setting of the Spanish National
Health Service. METHODS: Using the efﬁcacy data from the
CAPRIE study on the incidence of new cardiovascular events in
a group of patients with a previous MI, the sanitary and eco-
nomic consequences of the use of the two treatments, acetylsal-
icylic acid and clopidogrel, in this indication were modeled. The
costs used in this analysis refer to the year 2004 in the Spanish
National Health Service setting. RESULTS: In the base case, the
total cost of the acetylsalicylic acid treatment (€1515) was con-
siderably inferior to that of clopidogrel (€2942). The efﬁcacy
results in the subgroup of patients with a previous MI, are com-
paratively better with acetylsalicylic acid, however the difference
is not statistically signiﬁcant. With the assumptions adopted in
the base case, treatment with acetylsalicylic acid is superior
(better or equal efﬁcacy and less cost) when compared to treat-
ment with clopidogrel. The treatment with acetylsalicylic acid
was found to be superior to that of clopidogrel in all of the sce-
narios studied in the analysis of sensitivity. CONCLUSIONS:
The treatment with acetylsalicylic acid is effective, safe and cost-
effective in the secondary prevention of cardiovascular events 
in patients with a previous MI, and is still the ﬁrst choice
antiplatelet therapy for this indication.
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OBJECTIVE: to assess the economic and epidemiologic impact
of AMI in Friuli Venezia Giulia (FVG) a region of approximately
1.2 million inhabitants in the north-eastern Italy. METHODS:
All residents of FVG are registered in to Regional Health Service
(RHS) database, which keeps tracks of the use of medical care
admissions and reimbursement purposes. We selected residents
of FVG who had during year 2000 a ﬁrst AMI hospital admis-
sion and we followed them up till death, or 31 Dec 2004 (we a
priory excluded people who during the period 1995–1999 had
a previous CHD event). Mortality was investigated by collecting
information from Regional Citizen Register ﬁle. We obtained
information on medical costs from electronic databases of pre-
scriptions, hospitalizations, visits and diagnostic examinations in
FVG. Direct medical costs were quantiﬁed in the perspective of
the RHS and are expressed in Euro 2005. RESULTS: We enrolled
1185 patients with incident AMI (mean age 71 ± 13 y.o.), 59%
were men. The average cost person/year was €4913.32; 71.2%
attributable to hospitalisations, 19.3% to drugs. The 38.5%
patients died during the follow up period, with a mean age of
79.3 ± 10.1 statistically different (p < 0.0001) from survivors
(mean age 65.0 ± 12.0 y.o.). There was no signiﬁcant difference
in mortality between men and women adjusting for age. CON-
CLUSIONS: AMI imposes a huge economic burden on NHS and
society because of the large number of hospitalisation and the
high rate of mortality after the ﬁrst event. Future investigations
will be conduct to asses the relationships between comorbidity,
costs, therapy and survival.
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OBJECTIVES: To measure the direct costs of selected cardio-
vascular diseases within the Austrian health care system for the
ﬁrst year including the event, as well as from the second year
onward. METHODS: In this study, we analyzed the direct costs
of angina pectoris (AP) and myocardial infarction (MI) in
Austria. The direct costs were identiﬁed as resource consump-
tion for hospitalization, inpatient rehabilitation, outpatient treat-
ment, medication and transportation. Costs for inpatient care
were calculated according to the tariffs of the Austrian Diagno-
sis Related Group (DRG) system and the average number of allo-
cated points to AP and MI. Costs for inpatient rehabilitation
treatment were calculated with tariffs per day taken into account
the mean duration of stay. For outpatient treatment costs we con-
sidered the average number of consultations and the fee for
service, which is mainly paid by social insurance. Medication
costs were calculated and assessed with tariffs according to the
distribution of type and amount of prescribed agents. Costs for
transportation after the event were included with the tariffs per
ride. RESULTS: The total costs for the treatment of MI in the
ﬁrst year of event in 2004 were calculated with €8.960, rehabil-
itation contributing to 68% of this amount. Since there were no
inpatient rehabilitation costs to consider from the second year
onward, costs declined to approximately €1.490 per year. Costs
due to AP amounted about €2.180 for the ﬁrst year and declined
on average to €1.190 from the second year onward. CONCLU-
SIONS: In line with the study direct costs for cardiovascular dis-
eases were calculated for the ﬁrst time in Austria. As one of the
main ﬁnding we would like to point out the high direct inpatient
rehabilitation costs as the main cost driving factor for MI in the
ﬁrst year of event.
PCV79
POSTMYOCARDIAL INFARCTION CARDIAC REHABILITATION
IN LOW RISK PATIENTS. RESULTS WITH A COORDINATED
PROGRAM OF CARDIOLOGICAL AND PRIMARY CARE
Lafuente de Otto V1, Bravo Navas J2, Montiel Á2, Gómez-Doblas J2,
Collantes R2, González B2, Martínez M2
1Hospital Clinico Universitario Virgen de la Victoria, Málaga, Malaga,
Spain; 2Hospital Clinico Universitario Virgen de la Victoria. Centro de
Salud de Carranque, Málaga, Malaga, Spain
OBJECTIVES: To assess the efﬁcacy of cardiac rehabilitation
with a mixed primary and cardiological care program in patients
